> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca’s Evusheld No Longer OK for Emergency Use
- URL: https://www.fdaweb.com/astrazenecas-evusheld-no-longer-ok-for-emergency-use/
- Published: 2023-01-26T12:00:00.000Z
- Updated: 2026-09-14T18:13:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153635

FDA says AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) is not currently authorized for emergency use against Covid-19 infection in the U.S. until further notice. An agency [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us?ref=fdaweb.com) says data show Evusheld is unlikely to be active against certain SARS-CoV-2 variants that are projected to be responsible for more than 90% of current U.S. Covid infections.

“Today’s action to limit the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions, which can be potentially serious, at a time when fewer than 10% of circulating variants in the U.S. causing infection are susceptible to the product,” the notice says.